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Treatment-resistant depression (TRD)
is a major public health problem

Outcome & Treatment resistance

Confronting Clinical issues.
Disability
Quality of life
Suicide
Underdiagnosed
Causes,
neurobiology &
management
of ‘TreatmentUnder-treated
Resistance’

WHAT IS THE NATURE &
CHARACTERISTICS OF
TREATMENT RESISTANCE?

Resistance to What??

Measuring TRD: Staging Treatment Resistance
Stage I

Inadequate response to 1 monotherapy

Stage II

Inadequate response to 2 adequate monotherapy
trials (different classes)

Stage III

Stage II resistance plus inadequate response to 1
augmentation trial

Stage IV

Stage III resistance plus inadequate response to a
second augmentation trial

Stage V

Stage IV resistance plus inadequate response to
bilateral ECT

Adapted from: Thase ME, Rush AJ. J Clin Psychiatry. 1998;59(suppl 5):5
Souery D et al. Eur Neuropsychopharmacol. 1999;9:83

TRD: chronic, recurrent, debilitating
Lifetime Prevalance

Receive Treatment

Tx as per guideline

100
51

50

21

0
16.2

Trivedi MH, Lin EH, Katon WJ. Consensus recommendations for improving adherence, self-management, and
outcomes in patients with depression.CNS Spectr. 2007 Aug;12(8 Suppl 13):1-27

Non-response

Wijeratne C, Sachdev P.Treatment-resistant depression: critique of current approaches.Aust N Z J Psychiatry. 2008
Sep;42(9):751-62.

Nonremission is Common

Depression in Primary Care, Vol. 2. Treatment of Major Depression. Rockville, MD: US Dept. of

Health and Human Services, AHCPR Publication No. 93-0550, 1993.

Definitions of Response and Remission
The causes of TRD are not fully
understood.
% Reduction in Score
Remission

>75%

Response

50% - 74%

Partial Response

25% - 49%

Nonresponse
TRD
12 months Prevalence rate 2

<25%
>40%1
3%- Stage 1
2% - stage 2..

1.Taylor SM: Electroconvulsive therapy, brain-derived neurotrophic factor, and possible neurorestorative benefit of the clinical
application of electroconvulsive therapy. J ECT. 2008 Jun;24(2):160-5.
2. Nemeroff CB Prevalence and management of treatment-resistant depression.J Clin Psychiatry. 2007;68 Suppl 8:17-25

Paradigms Which Contribute to Faulty TRD Labeling

Parker et al 2005, J of Affect Dis Machado-Vieira R, Soares JC.Treatment-resistant mood disorders Rev Bras Psiquiatr. 2007 Oct;29 Suppl
2:S48-54

Predictors of Non-Response

CAN IT BE
IDENTIFIED?

Biology :

No specific neurobiology TRD.
Exploring newer brain targets
• NT: Dopamine, NMDA,
• Aminoacids : glutamate/glutamine/GABA cycling1
• Neuronal nitric oxide synthisase factor ( NOS) via Serotonine
signaling2
• Neuropeptides P/ Y3
• Endogenous modulators
• Beta 3 – adrenoreceptos ( agonist: amibegrone)
• Nicotinic receptors

IS THERE A SUBGROUP?
CLINICAL…OR
BIOLOGICAL??

1.Price B, et al Biological psychiatry, 2008 Dec
2.Ulak G, Pharmacol. Biochem behav.2008.
3.Nikisch G, Eur.Psychiatry.2008.23:356-9

Biological Changes in treatment Resistant Depression

Biology1, 2

Reduced global cortical folding5

N-methyl-D-aspartate (NMDA) receptor 4

Decreased Neurogenesis
1.Taylor SMElectroconvulsive therapy, brain-derived neurotrophic factor, and possible neurorestorative benefit of the clinical application of electroconvulsive
therapy.J ECT. 2008 Jun;24(2):160-5
2. Kitamura Y, Gomita Y. [Development of animal models of treatment-resistant depression in rats] Nihon Shinkei Seishin Yakurigaku Zasshi. 2008
Apr;28(2):93-100
3. Wijeratne C, Sachdev P. Treatment-resistant depression: critique of current approaches. Aust N Z J Psychiatry. 2008 Sep;42(9):751-62.
4.Maeng S, Zarate CA Jr. . The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular
mechanism underlying its antidepressant effects. Curr Psychiatry Rep. 2007 Dec;9(6):467-74.
5.Penttila J et al , J Psychiatry neurosci. 2009; 34(2):127-35

Decision tree for TRD

HOW TO CONFIRM
TREATMENT
RESISTANCE?

Diagnosing treatment resistance
Was
compliance
adequate?

Y

Was dosage
adequate?

Y

Was the
duration of
Tx adequate

Y
Was the
diagnosis
correct

Was the
assessment
comprehensive

Y

Was anything
interfering with
drug-kinetics?

Y

TRD - Common Diagnosis
1.Depressed Mood
2. Suicide ideation or attempt

Polarity
Psychosis

Substance
Physical
illness

Stress

Organic
Depression

Focus on ‘symptoms constellation ’
exclusion of physical & psychiatric conditions
Depression within
personality disorder

No manic or hypo
manic feature

Differentiate treatment resistance
from features of chronicity.

Towards a Comprehensive assessment of
Depressive disorder.
Outcome

…….

What clinical conditions
may present as treatment
resistant depression?

Bipolar Disorder is a
Multidimensional Illness
ManiaSubsyndromal
mania (hypomania)

WHAT CLINICAL CONDITIONS
Mania
CAN PRESENT AS TREATMENT
RESISTANT DEPRESSION?
Remission
Subsyndromal
depression

Depression

Lifelong management of this lifelong illness involves
targeting all phases of the disorder – atypical antipsychotics
can play a major role
Vieta E, et al. Bipolar Disord 2005; 7 Suppl 4:21-33.

Bipolar II Depression
Bipolar II disorder is a common disorder,
prevalence of approximately 3-5%.
Distinct clinical features
The key to diagnosis - recognition of past
hypomania,
• This is responsible for a significant rate of
missed diagnosis,
• It is unclear if bipolar II disorder is overrepresented in TRD

•
•
•
•

Bipolar II disorder: a review.
Berk M, Dodd S.
Bipolar Disord. 2005 Feb;7(1):11-21.

Bipolar diathesis for TRD

MISSED MANIA
BIPOLAR SPECTRUM
DISORDER

Manic symptoms
during depressive
episodes in 1,380
patients with bipolar
disorder: findings
from the STEP-BD.
Goldberg JF, Perlis
RH, Bowden
CL, Thase
ME, Miklowitz
DJ, Marangell
LB, Calabrese
JR, Nierenberg
AA, Sachs GS.
Am J Psychiatry.
2009 Feb;166(2):17381

Impact of Bipolar Disorder on Patients’ Lives
Onset is usually during late adolescence and early adulthood, a time at which individuals
are establishing their careers and building long-term relationships

Healthy life

Reduced by 12 years

Working life

Reduced by 14 years

Life expectancy

Reduced by 9 years

Employment problems

Twice as common

Divorce / separation

Twice as common

Results for patients developing bipolar disorder in their mid-20s
Coryell et al 1993; Scott 1995

Atypical depression
• 70% of depression with atypical features met with DSM IV criteria for
bipolar II
• 60% had antecedents cyclothymic & hyperthymic temperament
• Interpersonal sensitivity & atypical features were found to be powerful
prospective predictors of bipolar II

Anxious – bipolar co morbidity
The evolving bipolar spectrum
•
•
•
•

Prototype I,II ,III & IV
Bipolar I – full-blown mania
Bipolar 1 & ½ : depression with protected hippomania
Bipolar II : depression with hippomania

Outcome status:
What happens when TRD is treated?
• Not very encouraging.
• Nine outcome studies, Total N = 1279; follow-up duration - 1
to 10 years.
• In the short term, TRD was highly recurrent
• as many as 80% of those requiring multiple treatments
relapsing within a year of achieving remission.
• For those with a more protracted illness, the probability of
recovery within 10 years was about 40%.
• TRD was also associated with poorer quality of life and
increased mortality.
Fekadu A,et al What happens to patients with treatment-resistant depression?
A systematic review of medium to long term outcome studies Affect Disord. 2008 Nov 11.

How do we treat the
Treatment
resistance??
& what is the outcome?

Current (or future)
Treatment Options 2,3

(STAR*D)1 50% of "real world” MDD fail to achieve
remission, even after four
carefully monitored sequenced
treatments.

Antidepressants:
SSRI, TCA
MAOI, SNRI & others

1.Kennedy SH, Giacobbe P,Treatment resistant depression--advances in somatic therapies.Ann Clin Psychiatry. 2007 Oct-Dec;19(4):279-87.
2.Carvalho AF, Cavalcante JL, Castelo MS, Lima MC.Augmentation strategies for treatment-resistant depression: a literature review.J Clin Pharm
Ther. 2007 Oct;32(5):415-28
3.. Tadić A, Lieb K. [Pharmacological therapy for therapy-resistant depression. New developments] Nervenarzt. 2007 Nov;78 Suppl 3:551-63;

.

.Safety & efficacy of
antidepressants

1.Optimization
inadequate dose & inadequate duration
•
•
•
•
•

Only 11 percent of patients receive adequate therapeutic therapy.
Inadequate therapy - particularly prevalent in elderly patients.
The clinician need to maximize the dosage or duration of therapy.
Higher than recommended dosage: some patients benefit
An adequate duration has been defined by some - four to six weeks. -six weeks –10-12 weeks -- to elicit a full ADD response.

Selecting right ADD
Have the cytochrome P450 (CYP450) genotyping test
Papakostas GI,et al A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor,
with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
Eur Neuropsychopharmacol. 2008 Feb;18(2):122-7

.

Selectivity Ratios for Uptake Inhibitor
Antidepressants
(measured in vitro)
5 – HT selectivity

10000

1000

100

10

NA selectivity

0

Selectivity ratio

10

100

Understanding
the Illness

1000

10000

The way
Forward

Switch to another ADD? Which…??
•

1 in 4 patients on SSRI’s have a
response on 2nd drug:
–
–
–

•
•
•
•
•

Bupropion-SR
Sertraline
Venlafaxine-XR

Within class
1st SSRI may be ineffective/
intolerable
2nd SSRI may be effective/ tolerable
Out-of-class
SSRI ----> TCA = 30 to 50%
Papakostas GI et al Treatment of SSRI-resistant depression:
a meta-analysis comparing within- versus across-class switches
Biol Psychiatry. 2008 Apr 1;63(7):699-704.

four
clinical trials
(n = 1496)

non-SSRI
antidepressant
(bupropion,
mirtazapine,
venlafaxine)

Pooled remission
rates 28%
(for non-SSRIs)

SSRI

Pooled remission rate
23.5%

3/18/09

3. Combination Therapy 1

• Combination therapy involves the addition of a second antidepressant
agent to the therapeutic regimen.
• Concurrent administration of two or more antidepressant agents
(e.g., adding trazodone [Desyrel], desipramine [Norpramine] or bupropion
[Wellbutrin] to fluoxetine) may result in a different therapeutic response
than that produced by use of either drug alone.
• However, no double-blind, placebo-controlled studies recommend the
usefulness of this practice.
• In addition, this approach does not allow for adequate evaluation of
monotherapy and may lead to significant adverse effects or drug-drug
interactions
1.Berlim MT, Fleck MP, Turecki G.Current trends in the assessment and somatic treatment of resistant/refractory major
depression: an overview.Ann Med. 2008;40(2):149-59

4.Augmentation Therapy1
•

Involves adding a second agent, but one that is not routinely regarded as
an antidepressant.2

• Dopaminergic agents, 7
• atypical antipsychotics, 7
•
Psychostimulants, benzodiaze
pines/hypnotics, hormones
and
• Anticonvulsants. 7

•
•
•
•
•

Testosterone 1
Foliate 3
Omega 34
Lamotregene5
Olanzapine/fluoxetine6

1.Amiaz R, Seidman SN.Testosterone and depression in meCurr Opin Endocrinol Diabetes Obes. 2008 Jun;15(3):278-83.
2. Wijeratne C, Sachdev P. Treatment-resistant depression: critique of current approaches. Aust N Z J Psychiatry. 2008 Sep;42(9):751-62
3. Morris DW, Trivedi MH, Rush AJ. Folate and unipolar depression. J Altern Complement Med. 2008 Apr;14(3):277-85.
4.Owen C, Rees AM, Parker G The role of fatty acids in the development and treatment of mood disorders. Curr Opin Psychiatry. 2008 Jan;21(1):19-24.
5.McIntyre J, Moral MA. Spotlight on lamotrigine for depression.Drug News Perspect. 2006 Sep;19(7):427-30
6. Dodd S, Berk M. Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility. Expert Rev Neurother. 2008
Sep;8(9):1299-306
7. Carvalho AF, et al Augmentation strategies for treatment-resistant depression: a literature review . J Clin Pharm Ther. 2007 Oct;32(5):415-28

Crucial
questions

Progress
Shall I persist, increase or add?
100mgs Sertraline

Amitriptyline and clomipramine
are more effective than SSRIs
(but more side effects and more
toxic in overdose)
The difference is that these drugs
affect both serotonin (5HT) and
noradrenaline
Other drugs that have a similar effect
are:
Venlafaxine
Mirtazepine
Duloxetine

Licht & Qvitzau 2002

Are these also more effective?

Combining and Switching

Crucial
questions

4a.Lithium.
4b.Thyroid hormone: Low dose, short- term
Low dose
•

•
•
•
•
•
•
•
•
•

Enhances serotonin transmission
The thyroid hormone triiodothyronine (T3) appears to be a
Reduces
activity
of tetraiodothyronine
post-synaptic 5-HT (T4
receptors.
more
effective
than
)
Increasesinserotonin
levels for
in the
synaptic
Effective
small dosages;
example,
25cleft.
to 50 µg per day.
Response
of 30
to 65%response to TCA, MAOI, and SSRIs.
T3
may be rates
used to
augment
within 48inhours
3-6patients.
weeks
effective
50 toto6%0
Most research
support
Monitoring
thyroid
function
Least
used
T3
potentiates
noradrenergic activity,
Start
at 150 mgof action is not clearly understood.
Its
mechanism
Sr. level 0.4
to 0.8
Relatively
safe,
fewmEq/L
AE – allergic x 2-3 weeks
Aim for lower serum level

4c.Pindolol.
4d.Buspirone.
• Anxiolytic.
• The 5-HT1A postsynaptic antagonist
• No specific/intrinsic antidepressant effects.
• Accelerates the onset of action of ADD by
• Dosages of 15 to 30 mg /D x 3 Months :
preventing negative feedback
to the
rd
improved response – 2/3 of patients.
presynaptic 5-HT1A receptor. - higher
• Full agonist at the presynaptic autoreceptor
levels of serotonin in synapse.
and partial agonist at the postsynaptic
• At
dosages of 2.5 to 7.5 mg/D x 6 weeks,
autoreceptor.
•• AE
- < 10%extracellular serotonin
Decreases
concentrations over the short term.
.

4e.Pramipexole

•
•
•
•

Large effect size (0.6-1.1):
With a low switching in bipolar
patients (1% mania, 5% hypomania).
The pooled discontinuation rate - 9%.
Neuroprotective
Effects on sleep architecture.
SE in Parkinson’s disease

•
•
•
•

Sleep attacks,
Compulsive behaviors
Pathologic gambling,
Restless legs syndrome;

•

Psychosis

•

Aiken CB.Pramipexole in psychiatry: a systematic review of the
literature.J Clin Psychiatry. 2007 Aug;68(8):1230-6.

•

•

4f.Anticonvulsants

• Lamotregene
• Carbamezapine
• Triple Reuptake Inhibitors
(TRI)
Target all three of brain’s monoamines
(serotonin, norepinephrine, dopamine)
• Expected on the market by 2010
• Better efficacy and tolerability, faster
acting, less side effects, treats broader range of
symptoms
•

4g.Novel Antipsychotics
1- combination ( OFC) 2- Switch to AATPD
 SDA, beneficial
 50% Response
 25% Remission
 Olanzapine 1
 According to results,

Risperidone are reasonable
choices as augmentation agents
 With only aripiprazole currently
having an FDA( USA) indication
for this use.2

Aripiprazole, Olanzapine, and

Clozapine in medication- and electroconvulsive
therapy-resistant, depressed inpatients: a case series
•

Quante A, J Clin Psychopharmacol. 2007 Dec;27(6):715-7.

1. Selis MA, Peeters FP. Augmentation with atypical antipsychotics for the treatment of patients with a therapy-resistant depression: a
review] Tijdschr Psychiatr. 2008;50(4):213-22
2. Philip NS, Carpenter LL, Tyrka AR, Price LH. Augmentation of antidepressants with atypical antipsychotics: a review of the current
literature. J Psychiatr Pract. 2008 Jan;14(1):34-44

Summary of the Evidence Base for the Efficacy
of Atypical Antipsychotics in Bipolar Disorder
Maintenance / Continuation
Treatment

Acute Treatment
Mania

Depression

Mania

Depression

Quetiapine

++

++

++

++

Olanzapine

++

+

++

+

Risperidone

++

?

++

+?

Aripiprazole

++

–

++

–

Ziprasidone

++

?

?

?

Asenapine

++

?

?

?

Paliperidone

++

?

?

?

++ = at least one good RCT showing clinically significant effects
+ = at least one RCT showing some effect
- = RCT evidence of a lack of clinically significant effects
? = uncertain or no controlled data available

Health Canada Approved Indications for Agents Used in the
Treatment of Bipolar Disorder
Acute Bipolar
Depression

Acute Mania

Maintenance
Treatment

√

√
√
√

√*

√
√

√+

√

√

Agents
ATYPICALS
Clozapine
Olanzapine
Quetiapine (SEROQUEL XR)
Risperidone
Paliperidone
Ziprasidone
OTHER
Carbamazepine
Divalproex
Lamotrigine
Lithium
+ for use after treatment failure on traditional mood stabilizer
*See PM. Evaluation from 2 “time to relapse” trials with manic or
mixed index episode

This chart does not imply comparable efficacy or
safety profiles.
All brand names and product names used in this slide
are trade names, service marks, trademarks, or
registered trademarks of their respective owners.

BOLDER & EMBOLDEN (acute phase):
Change in MADRS Total Score
Rapid cycling
(n=393)

Non-rapid cycling
(n=1,814)

Improvement

LSM
change
from
baseline
to Week 8

*** ***

***

***

Quetiapine 300 mg
Quetiapine 600 mg
Placebo

*** p<0.001 vs placebo ITT, LOCF
Baseline values: Rapid cycling - quetiapine 300 mg, 29.4; 600 mg, 29.5;
placebo, 29.9
Non-rapid-cycling - quetiapine 300 mg, 28.7; 600 mg, 28.3; placebo, 28.9

BOLDER I & BOLDER II:MADRS Items at Week 8
‡§
‡§

At Week
1, significant
improvement
was seen in
6 out of 10
items‡

‡§
‡§
‡§
‡§
¶
§
§
§

Percentage Improvement at Week 8
* Montgomery-Asberg Depression Rating Scale.
† Data combined from two 8-week, multicenter, randomized, double–blind, placebo-controlled, monotherapy bipolar
depression trials.
P < 0.05 vs placebo at Week 1 § P < 0.001 vs placebo at Week 8 ¶ P < 0.05 vs placebo at Week 8.

ITT, MMRM**
Combined
Studies

Data on File, DA-SER-45.

How do we explain?

Why do Atypical antipsychotics have Antidepressant action?

A: Regional distribution of 5-HT System in the Brain??

Depression in schizophrenia : perspective in era of ‘atypical antipsychotics’. Siris ,S.G.AJP 2000 ;157

ECT
• The acute effect is well
established
• ECT in TRD
– Continuation Tx is required
• average 14.6 months in
– In 1 study, within 24 weeks of
their current episodes
achieving remission, 64%
• 6.2 years of their lifetime in
relapsed.1

depression.
• Failed to respond to an
average of 5.4 different ADD
• (65.8%) responded
• (53.3%) achieved remission
.
–

– TRD is predictive of post-ECT
relapse
• TRD patients at high risk for
relapse: only 32%
maintained response in next
12 months2

Khalid N The effectiveness of electroconvulsive
therapy in treatment-resistant depression: a
naturalistic study. J ECT. 2008 Jun;24(2):141-5.
1.
2.

Sackeim et al, JAMA,2001;285:1299-1307.
Prudic J, et al Biol.Psychiatry,2004;55:301-312.

Deep Brain Stimulation (DBS):
The Surgical option
•• FDA
for Parkinson’s
&
Five approved
potential targets
– identified
tremors
:
•• Investigational
for OCD TRD
Ventral striatum/nucleus
• Stereotactic
accumbens, target from MRI
•• Two
chest wall
internal
pulse(area
Subgenual
cingulate
cortex
generator
25),
•• Burr
holethalamic
in skull for
electrode
Inferior
peduncle,
placement
• Rostral cingulate cortex (area
• Stimulation
24a), and parameter
programmed by computer
• through
Lateral habenula.
a ‘WAND’
Hauptman JS, DeSalles AA, Espinoza R, Sedrak M, Ishida W.Potential surgical targets for
deep brain stimulation in treatment-resistant depression.Neurosurg Focus. 2008;25(1):E3

Deep Brain stimulation
Efficacy: [Subcallosal cingulate
gyrus ] for treatment-resistant
depression
• There were both early and
progressive benefits to DBS. One
month after surgery,
• 35% - response
• 10%- remission.
• Six months after surgery,
• 60% -responders
• 35% -remission,
• Benefits maintained at 12 months.

•
•

Reduced activity in this region (shown in blue at bottom) is seen with six months of chronic deep
brain stimulation.
This reduction correlates with the antidepressant effect of the treatment.
(Images courtesy of Helen Mayberg)

•

www.dana.org/uploadedImages/Images/Spotlight_Images/Cerebrum_DBS_2008-03_spot.jpg

•

rTMS
•
•
•
•
•
•
•
•
•
•
•
•
•

No general anesthesia
Outpatient procedure
Lower energy requirement.
"the magnetic field can be highly focused,
No social stigma
Specific targeted stimulation
No convulsion requirement
Minimal side effects such as mild headache
and discomfort at the site of stimulation
No known adverse effects on cognition
Potential advantages - as an add-on
The long term effectiveness of rTMS for
severe depression is unknown.
The use, if any, of continued maintenance
therapy is unknown.
Long term pragmatic patient outcomes such
as time to further treatment,

TMS add-on on escitalopram
TRD with 2 failed
trial of ADD
GR II- 15 sessions
TMS+
20 mg ESCT

For 3
weeks
duration

Gr !- Sham 15 sessions
TMS
+ 20 mg ESCT

Follow up of 3 weeks
Outcome assessment by HAM-D
shows effects size of 0.7
Bretlau LG et al Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major
depression: a double-blind, randomised, sham-controlled trial.
Pharmacopsychiatry. 2008 Mar;41(2):41-7

Vegus Nerve
stimulation ( VNS)
•
•
•

•
•
•
•
•

Well tolerated
A safe and feasible procedure, despite
its limitations
Acts via innervation of the nucleus
tractus solitarius, with secondary
projections to limbic and cortical
structures that are involved in mood
regulation
Efficacy data not randomized
Surgical procedure
Non-acute antidepressant effect
MRI contraindication
Battery

1.Daban C, et al Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review. J Affect Disord. 2008
Sep;110(1-2):1-15
2.Nemeroff CBVNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms.
Neuropsychopharmacology. 2006 Jul;31(7):1345-55.

Preventing treatment resistance
Treating treatment resistance

